HC Wainwright & Co. Reiterates Buy on Kronos Bio, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Kronos Bio (NASDAQ:KRON) and maintained a $9 price target on the stock.
November 27, 2023 | 11:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on Kronos Bio and maintained a $9 price target.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on KRON's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100